UB Paderborn / Katalog / Suche / in CDI

Germline BAP1 mutations predispose also to multiple basal cell carcinomas

Clinical genetics, 2015-09, Vol.88 (3), p.273-277

2015

Volltextzugriff (PDF)

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

Annals of oncology, 2018-10, Vol.29, p.viii76-viii76

2018

Volltextzugriff (PDF)

Comment répondre aux demandes de mastectomie prophylactique controlatérale après un cancer du sein hors prédisposition génétique ? Perspectives éthiques et cliniques

Psycho-oncologie, 2019-06, Vol.13 (2), p.129-135

2019

Volltextzugriff (PDF)

Familial hematological malignancies: ASXL1 gene investigation

Clinical & translational oncology, 2016-04, Vol.18 (4), p.385-390

2016

Volltextzugriff (PDF)

The contribution of germline rearrangements to the spectrum of BRCA2 mutations

Journal of medical genetics, 2006-09, Vol.43 (9), p.e49-e49

2006

Volltextzugriff (PDF)

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

Human mutation, 2018-05, Vol.39 (5), p.593-620

2018

Volltextzugriff (PDF)

High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome

Journal of medical genetics, 2013-04, Vol.50 (4), p.255-263

2013

Volltextzugriff (PDF)

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

American journal of obstetrics and gynecology, 2021-07, Vol.225 (1), p.51.e1-51.e17

2021

Volltextzugriff (PDF)

Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families

Journal of medical genetics, 2008-08, Vol.45 (8), p.535-538

2008

Volltextzugriff (PDF)

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

Breast cancer research : BCR, 2020-01, Vol.22 (1), p.8-8, Article 8

2020

Volltextzugriff (PDF)

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (3), p.624-638

2020

Volltextzugriff (PDF)

Cancer genetics: estimation of the needs of the population in France for the next ten years

Bulletin du cancer, 2009-09, Vol.96 (9), p.875

2009

Volltextzugriff (PDF)

Molecular study of CEPBA in familial hematological malignancies

Familial cancer, 2009-12, Vol.8 (4), p.581-584

2009

Volltextzugriff (PDF)

1003P - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Annals of oncology, 2019-10, Vol.30, p.v410-v410

2019

Volltextzugriff (PDF)

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Annals of oncology, 2019-10, Vol.30, p.v410

2019

Volltextzugriff (PDF)

Tamoxifen and risk of endometrial cancer

The Lancet (British edition), 2001-01, Vol.357 (9249), p.66-67

2001

Volltextzugriff (PDF)

Abstract P3-03-05: Association between BRCA1 and BRCA2 mutations and survival in breast cancer patients according to molecular subtype

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-03-05

2018

Volltextzugriff (PDF)

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

British journal of cancer, 2019-07, Vol.121 (2), p.180-192

2019

Volltextzugriff (PDF)

Mutation analysis of PALB2 gene in French breast cancer families

Breast cancer research and treatment, 2015-12, Vol.154 (3), p.463-471

2015

Volltextzugriff (PDF)

Location of mutation in BRCA2 gene and survival in patients with ovarian cancer

Annals of oncology, 2017-09, Vol.28, p.v335-v335

2017

Volltextzugriff (PDF)

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

Breast cancer research : BCR, 2014-12, Vol.16 (6), p.3416-3416, Article 3416

2014

Volltextzugriff (PDF)

Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

Breast cancer research and treatment, 2017-01, Vol.161 (1), p.117-134

2017

Volltextzugriff (PDF)

Classification des familles de type sein–ovaire sans mutation constitutionnelle de BRCA1/2 identifiée, pour le niveau de risque de cancer du sein : apport d’une stratégie d’évaluation multicritères s’appuyant sur une méthode d’analyse factorielle

Revue d'épidémiologie et de santé publique, 2017-06, Vol.65, p.S129-S130

2017

Volltextzugriff (PDF)

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers

Frontiers in oncology, 2018-10, Vol.8, p.490-490

2018

Volltextzugriff (PDF)

Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study

European journal of human genetics : EJHG, 2016-08, Vol.24 (9), p.1324-1329

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Germline BAP1 mutations predispose also to multiple basal cell carcinomas

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

Comment répondre aux demandes de mastectomie prophylactique controlatérale après un cancer du sein hors prédisposition génétique ? Perspectives éthiques et cliniques

Familial hematological malignancies: ASXL1 gene investigation

The contribution of germline rearrangements to the spectrum of BRCA2 mutations

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

Cancer genetics: estimation of the needs of the population in France for the next ten years

Molecular study of CEPBA in familial hematological malignancies

1003P - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Tamoxifen and risk of endometrial cancer

Abstract P3-03-05: Association between BRCA1 and BRCA2 mutations and survival in breast cancer patients according to molecular subtype

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

Mutation analysis of PALB2 gene in French breast cancer families

Location of mutation in BRCA2 gene and survival in patients with ovarian cancer

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

Classification des familles de type sein–ovaire sans mutation constitutionnelle de BRCA1/2 identifiée, pour le niveau de risque de cancer du sein : apport d’une stratégie d’évaluation multicritères s’appuyant sur une méthode d’analyse factorielle

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers

Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study

Suchergebnisse filtern